Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:12:59.542Z.
Calculation as of: 2026-10-06T19:12:59.542Z.
Quote observation: 2026-10-06T19:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a9e17458a879267a616e624bc5dc95fe16f3f590d16343b45edf8fcc71148c1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$356.12M
Price/FCF Ratio
12.18
TTM Avg
32.60
3Y Avg
51.28
5Y Avg
207.97
Market Cap
$357.87M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$357.08M
Price/FCF Ratio
N/A
TTM Avg
54.19
3Y Avg
39.66
5Y Avg
37.45
Market Cap
$359.44M
Price/FCF Ratio
N/A
TTM Avg
6.69
3Y Avg
6.69
5Y Avg
6.69
Market Cap
$351.98M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $356.10M | N/A | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $356.12M | 12.18 | 32.60 | 51.28 | 207.97 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $357.87M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.08M | N/A | 54.19 | 39.66 | 37.45 |
| Embecta Corp. (EMBC)vs › | $357.44M | 2.17 | 2.83 | 26.37 | 19.21 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.44M | N/A | 6.69 | 6.69 | 6.69 |
| Turn Therapeutics Inc. (TTRX)vs › | $352.09M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $351.98M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $364.12M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $345.61M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
